Executive admits Merck considered reformulating Vioxx

This article shows that Merck considered reformulating Vioxx to add an aspririn-like compound to the drug in order to better protect the heart. The revelation came during testimony by one of Merck's lead researchers.

As the article notes:

"On Monday, she discussed minutes from meetings in which top executives of the pharmaceutical company discussed reformulating Vioxx with an aspirin-like compound. The company, meanwhile, was busy touting Vioxx for its ease on the stomach. "